<DOC>
	<DOCNO>NCT02444455</DOCNO>
	<brief_summary>Phase I-II Clinical Trial - Safety efficacy umbilical-cord-derived mesenchymal stem cell ( UC-MSC ) patient Acute Lung Injury , open label , control prospective study .</brief_summary>
	<brief_title>Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy Acute Lung Injury</brief_title>
	<detailed_description>Phase I-II Clinical Trial - Safety efficacy umbilical-cord-derived mesenchymal stem cell ( UC-MSC ) patient acute lung injury , open label , control prospective study . Every patient maintain standard treatment acute lung injury , maximum tolerated dosage without side effect . The day infusion consider day zero . From moment , followup divide 2,7,14 day . Clinical result analyze completion 14 day followup .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Lung Injury</mesh_term>
	<criteria>Signed informed consent Age 35 70 Acute onset within 7 day . Oxygenation index:200＜PaO2/FiO2≤300mmHg ; alveolararterial oxygen difference : P ( Aa ) O2 &gt; 35mmHg Bilateral infiltrates chest radiography No cardiac failure Declined sign informed consent Socially mentally disabilities Malignant disease Combined severe infectious disease Patients positive blood test Hepatitis B Hepatitis C HIV tuberculosis time screen Pregnant perinatal woman Severe diseases major organ</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>cellular therapy</keyword>
	<keyword>acute lung injury</keyword>
	<keyword>acute respiratory distress snydrome</keyword>
	<keyword>human umbilical cord mesenchymal stem cell</keyword>
	<keyword>phase 1/2 clinical study</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
	<keyword>ALI</keyword>
	<keyword>ARDS</keyword>
</DOC>